Lexicon expects delay in FDA feedback on additional data for its diabetes drug
Refinitiv1分未満で読めます
Lexicon Pharmaceuticals 
LXRX said on Monday the U.S. Food and Drug Administration requires more time to review the company's previously submitted additional data on its experimental drug, Zynquista, for patients with type 1 diabetes.
ログイン、もしくは永年無料のアカウントを作成して、このニュースを読みましょう